RUTHERFORD, N.J., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, initiated two additional multi-year clinical trial contracts with biopharmaceutical customers. The Company estimates that the new contracts increase its total SelectOneTM pipeline to over $13 million in revenue over the next two years.
Help employers find you! Check out all the jobs and post your resume.
